SG11202002975YA - Treatment of focal segmental glomerulosclerosis with ccr2 antagonists - Google Patents

Treatment of focal segmental glomerulosclerosis with ccr2 antagonists

Info

Publication number
SG11202002975YA
SG11202002975YA SG11202002975YA SG11202002975YA SG11202002975YA SG 11202002975Y A SG11202002975Y A SG 11202002975YA SG 11202002975Y A SG11202002975Y A SG 11202002975YA SG 11202002975Y A SG11202002975Y A SG 11202002975YA SG 11202002975Y A SG11202002975Y A SG 11202002975YA
Authority
SG
Singapore
Prior art keywords
treatment
focal segmental
segmental glomerulosclerosis
ccr2 antagonists
ccr2
Prior art date
Application number
SG11202002975YA
Other languages
English (en)
Inventor
Zhenhua Miao
Thomas Schall
Rajinder Singh
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11202002975YA publication Critical patent/SG11202002975YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
SG11202002975YA 2017-10-11 2018-10-10 Treatment of focal segmental glomerulosclerosis with ccr2 antagonists SG11202002975YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570778P 2017-10-11 2017-10-11
PCT/US2018/055244 WO2019075086A1 (en) 2017-10-11 2018-10-10 TREATMENT OF FOCAL SEGMENTAL GLOBEROSCLEROSIS WITH CCR2 ANTAGONISTS

Publications (1)

Publication Number Publication Date
SG11202002975YA true SG11202002975YA (en) 2020-04-29

Family

ID=66101688

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002975YA SG11202002975YA (en) 2017-10-11 2018-10-10 Treatment of focal segmental glomerulosclerosis with ccr2 antagonists

Country Status (17)

Country Link
US (3) US10758540B2 (enExample)
EP (1) EP3694504A4 (enExample)
JP (1) JP2020536919A (enExample)
KR (1) KR20200070299A (enExample)
CN (1) CN111417389A (enExample)
AR (1) AR113440A1 (enExample)
AU (1) AU2018347361A1 (enExample)
BR (1) BR112020007183A2 (enExample)
CA (1) CA3078809A1 (enExample)
CL (1) CL2020000974A1 (enExample)
IL (1) IL273717A (enExample)
MX (1) MX386699B (enExample)
RU (1) RU2020113612A (enExample)
SG (1) SG11202002975YA (enExample)
TW (1) TW201922246A (enExample)
WO (1) WO2019075086A1 (enExample)
ZA (1) ZA202002049B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102754341B1 (ko) * 2016-11-23 2025-01-13 케모센트릭스, 인크. 국소 분절 사구체경화증의 치료 방법
EP3694504A4 (en) * 2017-10-11 2021-07-14 ChemoCentryx, Inc. TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN116173014A (zh) 2019-12-17 2023-05-30 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
AU2022244585A1 (en) * 2021-03-23 2023-09-21 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3901855A (en) 1974-08-07 1975-08-26 Us Air Force Preparation of polybenzimidazoles
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4227437A (en) 1977-10-11 1980-10-14 Inloes Thomas L Frequency detecting apparatus
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4403607A (en) 1980-05-09 1983-09-13 The Regents Of The University Of California Compatible internal bone fixation plate
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPS61113060A (ja) 1984-11-08 1986-05-30 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
DE3825041A1 (de) 1988-07-20 1990-02-15 Schering Ag Pyrido(3,2-e)(1,2,4)triazolo(1,5-a)pyrimidin- 2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, pflanzenwachstumsregulierender und fungizider wirkung
DE3924424A1 (de) 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
JPH04364168A (ja) 1990-08-08 1992-12-16 Taisho Pharmaceut Co Ltd スルホンアミドピリジン化合物
ATE167473T1 (de) 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
JPH06145145A (ja) 1991-12-27 1994-05-24 Ishihara Sangyo Kaisha Ltd アミノトリフルオロメチルピリジン誘導体又はその塩、それらの製造方法及びそれらを含有するホスホリパーゼａ▲２▼阻害剤、抗炎症剤並びに抗膵炎剤
JPH06135934A (ja) 1991-12-27 1994-05-17 Ishihara Sangyo Kaisha Ltd ピリジン誘導体又はその塩を含有するホスホリパーゼ▲ａ２▼阻害剤、抗炎症剤又は抗膵炎剤
US6159686A (en) 1992-09-14 2000-12-12 Sri International Up-converting reporters for biological and other assays
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
US7888466B2 (en) * 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
JP3421349B2 (ja) 1996-02-22 2003-06-30 テュラリク インコーポレイテッド ペンタフルオロベンゼンスルホンアミドおよび類縁体
US5780488A (en) 1996-04-03 1998-07-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69737656T2 (de) 1996-09-10 2008-01-03 Theodor Kocher Institut Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
ZA9710197B (en) 1996-11-13 1999-05-12 Dow Agrosciences Llc N-arylsulfilimine compounds and their use as catalysts in the preparation of n-arylarylsulfonamide compounds
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6380206B1 (en) 1998-11-23 2002-04-30 Cell Pathways, Inc. Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives
JP2000159665A (ja) 1998-11-27 2000-06-13 Nippon Kayaku Co Ltd リウマチの予防または治療剤
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU779516B2 (en) 1999-06-28 2005-01-27 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001335714A (ja) 2000-03-22 2001-12-04 Fuji Photo Film Co Ltd アゾ色素、その製造方法、インクジェット用インク、インクジェット記録方法
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
CA2409762A1 (en) 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
JP3699910B2 (ja) 2000-10-31 2005-09-28 株式会社東芝 データ伝送装置、データ伝送方法及びプログラム
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
EP1717583A3 (en) 2001-06-07 2007-10-10 ChemoCentryx Inc Cell migration assay
JP2003040726A (ja) 2001-07-26 2003-02-13 Daito Kasei Kogyo Kk 化粧料
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
AU2002358390A1 (en) 2001-12-18 2003-06-30 Astrazeneca Ab Novel compounds
US7119112B2 (en) 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
EP1507756B1 (en) 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US20070021466A1 (en) 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US20060111351A1 (en) 2002-11-18 2006-05-25 Solomon Ungashe Aryl sulfonamides
EP1562940B1 (en) 2002-11-18 2007-05-30 ChemoCentryx Inc Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
AU2003299797A1 (en) 2002-12-19 2004-07-14 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
AU2003290346A1 (en) 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
EP1644008B1 (en) 2003-05-29 2011-12-21 Abbott Laboratories Continuous dosing regimen with abt-751
WO2005004810A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US20060173019A1 (en) 2005-01-14 2006-08-03 Solomon Ungashe Heteroaryl sulfonamides and CCR2
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
WO2007014008A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007014054A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20070219245A1 (en) 2006-03-14 2007-09-20 Cuifen Hou Method of use for substituted dipiperidine ccr2 antagonists
WO2008008394A1 (en) 2006-07-12 2008-01-17 Transform Pharmaceuticals, Inc. Tizanidine succinate salt forms and methods of making and using the same
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
WO2009009740A1 (en) 2007-07-12 2009-01-15 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation
NO2321351T3 (enExample) 2008-08-18 2018-03-31
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PT2513093E (pt) 2009-12-17 2014-10-22 Boehringer Ingelheim Int Novos antagonistas do receptor ccr2 e suas utilizações
CN103328479A (zh) * 2010-09-27 2013-09-25 普罗克斯马根有限公司 7-羟基-吡唑并[1，5-a]嘧啶化合物及其作为ccr2受体拮抗剂的用途
EP2663304B1 (en) 2011-01-11 2019-11-20 Dimerix Bioscience Pty Ltd Combination therapy
JP2017502075A (ja) 2013-11-04 2017-01-19 ノクソン ファーマ エージー 腎障害治療の手段および方法
RS62809B1 (sr) 2015-05-21 2022-02-28 Chemocentryx Inc Modulatori ccr2
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
KR102754341B1 (ko) * 2016-11-23 2025-01-13 케모센트릭스, 인크. 국소 분절 사구체경화증의 치료 방법
EP3694504A4 (en) * 2017-10-11 2021-07-14 ChemoCentryx, Inc. TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS

Also Published As

Publication number Publication date
CN111417389A (zh) 2020-07-14
RU2020113612A (ru) 2021-11-12
US10758540B2 (en) 2020-09-01
US20210000834A1 (en) 2021-01-07
CL2020000974A1 (es) 2020-08-14
EP3694504A1 (en) 2020-08-19
TW201922246A (zh) 2019-06-16
RU2020113612A3 (enExample) 2022-04-29
WO2019075086A1 (en) 2019-04-18
MX386699B (es) 2025-03-19
CA3078809A1 (en) 2019-04-18
AR113440A1 (es) 2020-05-06
IL273717A (en) 2020-05-31
US11382915B2 (en) 2022-07-12
ZA202002049B (en) 2021-10-27
AU2018347361A1 (en) 2020-04-30
KR20200070299A (ko) 2020-06-17
EP3694504A4 (en) 2021-07-14
MX2020003502A (es) 2021-09-30
JP2020536919A (ja) 2020-12-17
BR112020007183A2 (pt) 2020-09-24
US20220296601A1 (en) 2022-09-22
US20190134042A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
ZA202002049B (en) Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
DK3507291T3 (da) Kondenserede bicykliske sgc-stimulatorer
IL266751A (en) A method for the treatment of focal segmental tuberous sclerosis
BR112016020055A2 (pt) cobertura de polietileno reticulado por radiação
GB201608885D0 (en) Treatment
IL281274A (en) Methods for treating diuretic resistance
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
GB2547884B (en) Follow focus
GB201711374D0 (en) Dynamically adjustable focal spot
IL272738A (en) treatment regimens
IL252899A0 (en) Cross-linked polydiallyamine copolymers for the treatment of type 2 diabetes
IL266292A (en) treatment regimens
PL3580182T3 (pl) Uzdatnianie wody
IL274496A (en) macro carrier
IL256321A (en) Method of treating primary focal segmental glomerulosclerosis
HK40036925A (en) Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
MA39011A (fr) Parasol pour chromothérapie
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
GB201609851D0 (en) Water treatment
ZA201804726B (en) Water treatment facility
ZA201703047B (en) The treatment of water
ZA201706977B (en) Water treatment
ZA201702594B (en) Water treatment
GB201614103D0 (en) Water treatment
GB201610270D0 (en) Programming of devices